Edward Lewiecki, MD
Internal Medicine · Albuquerque, NMNPI 1861441735
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $316,684 of the $490,644 with a category attached, or 64.5%. 29 manufacturers reported payments, led by Amgen at 36.0% of the total. Among internal medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 755 payments — averaging $649.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$177K
- Ascendis Pharma Endocrinology Inc$97K
- Kyowa Kirin, Inc.$93K
- Radius Health, Inc.$75K
- AstraZeneca$33K
- UCB SA$5K
- plus $12K from 23 others
Across 262 payments — averaging $3955.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$635K
- Teva Pharmaceuticals USA, Inc.$214K
- Radius Health, Inc.$141K
- Amgen$37K
- Sanofi$11K
What the payments were for
- Consulting fees$99,71820%
- Speaking & faculty fees$316,68465%
- Travel & lodging$45,3359%
- Food & beverage$14,0073%
- Education$14,8993%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 199 | $176,694 |
| Ascendis Pharma Endocrinology Inc | 83 | $96,670 |
| Kyowa Kirin, Inc. | 139 | $92,679 |
| Radius Health, Inc. | 178 | $74,976 |
| AstraZeneca(2 entities) | 86 | $32,821 |
| UCB SA | 3 | $4,880 |
| Samsung Bioepis Co., Ltd. | 1 | $4,250 |
| Novo Nordisk Health Care AG | 2 | $3,500 |
| Celltrion, Inc. | 1 | $1,500 |
| Bayer | 3 | $856 |
| Agios Pharmaceuticals, Inc. | 1 | $416 |
| Organon | 1 | $228 |
| Pfizer | 13 | $189 |
| Novo Nordisk | 13 | $176 |
| Ultragenyx Pharmaceutical Inc. | 6 | $169 |
| Shire North American Group Inc | 1 | $105 |
| Corcept Therapeutics | 7 | $96 |
| Pharmacosmos Therapeutics Inc. | 1 | $93 |
| Ipsen Biopharmaceuticals, Inc | 3 | $68 |
| Boehringer Ingelheim | 2 | $53 |
| Lilly USA, LLC | 2 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Johnson & Johnson | 2 | $37 |
| AbbVie | 1 | $23 |
| Astellas Pharma US Inc | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| GSK | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$490,644 in reported general payments places this provider in the 95th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 12 | $1,680,304 |
| TymlosAbaloparatide | 100 | $271,731 |
| ForteoTeriparatide | 16 | $67,869 |
| Alendronate Sodium | 188 | $3,992 |
| Risedronate Sodium | 18 | $1,569 |
| Raloxifene Hcl | 12 | $438 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 13 | $207 |
| Levothyroxine Sodium | 11 | $203 |
| Lisinopril | 15 | $151 |
| Single Use SwabAlcohol Antiseptic Pads | 14 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq | $32,821 | $1,680,30412 claims |
| Radius Health, Inc.Tymlos | $74,976 | $271,731100 claims |
| Lilly USA, LLCForteo | $49 | $67,86916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 578 internal medicine providers in New Mexico.
Other internal medicine in Albuquerque
- James AdairAlbuquerque$108K
- Gulshan ParasherAlbuquerque$66K
- Mark WalkerAlbuquerque$24K
- Joao TeixeiraAlbuquerque$18K
- Karla AlmarazAlbuquerque$18K
- David SosaAlbuquerque$11K
- Revati ReddyAlbuquerque$7K
- Ross DavidsonAlbuquerque$7K
- Edmee RodriguezAlbuquerque$6K
- Anthony ChuangAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.